EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade

Immune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve therapeutic efficacy. The combination of antiangiogenic agents and ICB has demonstrated efficacy in several cancers. To improve the mechanistic un...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabasum, Saba, Thapa, Dinesh, Giobbie-Hurder, Anita, Weirather, Jason L., Campisi, Marco, Schol, Pieter J., Li, Xiaoyu, Li, Jingjing, Yoon, Charles H., Manos, Michael P., Barbie, David A., Hodi, F. Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618652/
https://www.ncbi.nlm.nih.gov/pubmed/37728484
http://dx.doi.org/10.1158/2326-6066.CIR-23-0171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618652/
https://www.ncbi.nlm.nih.gov/pubmed/37728484
http://dx.doi.org/10.1158/2326-6066.CIR-23-0171

Ejemplares similares